MCCM
ACAD icon

Morgan Creek Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Morgan Creek Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
+9,395
New +$207K 0.16% 9

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Creek Capital Management's ACAD Position: Q2 2026 in Review

Morgan Creek Capital Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 9,395 shares worth $238K. The stake represents 0.16% of the portfolio and ranks #9 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Morgan Creek Capital Management held 9,395 shares of Acadia Pharmaceuticals worth $238K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Morgan Creek Capital Management position in Q2 2026.
  • Acadia Pharmaceuticals made up 0.16% of Morgan Creek Capital Management's portfolio in Q2 2026, its #9 holding.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Morgan Creek Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.